Zevra completes Acer acquisition; pro forma net loss $59.5M for 9-mo 2023

ZEVRA THERAPEUTICS, INC.

Pro forma net loss of $59.5M for nine months ended Sep 30, 2023; $80.7M for FY 2022.
Acer acquisition closed Nov 17, 2023; exchange ratio 0.1210 Zevra shares per Acer share plus CVR.
Pro forma shares outstanding ~37.8M; Zevra issued ~2.96M shares for Acer equity.
Zevra purchased Acer's SWK term loans ($18.2M) and Marathon convertible notes ($12.0M).
Bridge loan of $10M provided to Acer; $1.5M anniversary payment due to Relief Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.